OncoMatch/Clinical Trials/NCT05766800
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Is NCT05766800 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for locally advanced.
Treatment: Serplulimab · Carboplatin · Pemetrexed · Nab-paclitaxel · Liposomal paclitaxel — For unresectable locally-advanced non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether surgery can provide survival benefit for patients with tumors initially unresectable transformed into resectable ones after chemoimmunotherapy. This trial aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment
Lab requirements
Blood counts
good function of other main organs (liver, kidney, blood system, etc.)
Kidney function
good function of other main organs (liver, kidney, blood system, etc.)
Liver function
good function of other main organs (liver, kidney, blood system, etc.)
Patients with good function of other main organs (liver, kidney, blood system, etc.)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify